Lutetium-177-PSMA-I&T

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameLutetium-177-PSMA-I&T
Drug Alias NameN/A
ClassificationBiologicsRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic NeoplasmsSalivary Gland NeoplasmsCarcinoma, Adenoid Cystic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsCyprus
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRadboud University Nijmegen
China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical CenterWeill Medical College of Cornell University
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsSalivary Gland NeoplasmsCarcinoma, Adenoid Cystic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A